Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Apellis Pharmaceuticals Inc.

www.apellis.com

Latest From Apellis Pharmaceuticals Inc.

Finance Watch: Expect A Busy First Half For 2020 IPOs

Public Company Edition: At the J.P. Morgan Healthcare Conference and Biotech Showcase it was noted that the US IPO market is likely to be less active in the second half of the year as election risk chills investment. Also, Apellis leads recent follow-on offerings.

Financing Business Strategies

Apellis Comes Closer To Taking On Alexion In PNH

Besting Alexion’s Soliris in a head-to-head Phase III trial portends a place in the market for Apellis’ competitor in paroxysmal nocturnal hemoglobinuria. But challenges dog both companies.

Research & Development Clinical Trials

Sanofi’s Sutimlimab Shows Promise In Rare Blood Disorder

A Phase III rare-disease hit for Sanofi marks the first of a number of orphan drug read-outs expected in the coming year.

Clinical Trials Research & Development

Finance Watch: Two New IPOs – IGM In the US, Henlius In Hong Kong – Gross Nearly $600m

Public Company Edition: IGM raised $175m to advance its IgM antibodies and Henlius brought in $410m for its novel drug and biosimilar platforms. Also, Acadia follow-on brings in $250m, PTC sells $350m worth of stock and debt, and Karyopharm royalty deal totals $150m.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Immune Disorders
  • Ophthalmic
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Apellis Pharmaceuticals Inc.
  • Senior Management
  • Cedric Francois, MD, PhD, Pres. & CEO
    Timothy Sullivan, CFO
    Pascal Deschatelets, PhD, COO
    David Watson, VP, Corp. Dev.
    Federico Grossi, CMO
  • Contact Info
  • Apellis Pharmaceuticals Inc.
    Phone: (617) 977-5700
    100 5th Ave
    Ste. A
    Waltham, MA 02451
    USA
UsernamePublicRestriction

Register